165 related articles for article (PubMed ID: 37879236)
61. Enhancing Radioiodine Incorporation in
Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
[No Abstract] [Full Text] [Related]
62. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
Liu J; Liu Y; Lin Y; Liang J
Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
[TBL] [Abstract][Full Text] [Related]
63. PSMA Expression in Differentiated Thyroid Cancer: Association With Radioiodine, 18FDG Uptake, and Patient Outcome.
Ciappuccini R; Saguet-Rysanek V; Giffard F; Licaj I; Dorbeau M; Clarisse B; Poulain L; Bardet S
J Clin Endocrinol Metab; 2021 Nov; 106(12):3536-3545. PubMed ID: 34331544
[TBL] [Abstract][Full Text] [Related]
64. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
65. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
[TBL] [Abstract][Full Text] [Related]
66. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
67. Effect of monocarboxylate transporter-1 on the biological behavior of iodine-refractory thyroid carcinoma.
Li Q; Xu B; Tang Y; Li Y; Ying H
Transl Cancer Res; 2021 Nov; 10(11):4914-4928. PubMed ID: 35116343
[TBL] [Abstract][Full Text] [Related]
68. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.
Hurst Z; Liyanarachchi S; He H; Brock P; Sipos J; Nabhan F; Kebebew E; Green P; Cote GJ; Sherman S; Walker CJ; Chang YS; Xue S; Hollingsworth B; Li W; Genutis L; Menq E; de la Chapelle A; Jhiang SM
Thyroid; 2019 Apr; 29(4):530-539. PubMed ID: 30654714
[TBL] [Abstract][Full Text] [Related]
69. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer.
Sacks W; Braunstein GD
Endocr Pract; 2014 Mar; 20(3):263-75. PubMed ID: 24126232
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of integrin α
Liang Y; Jia X; Wang Y; Liu Y; Yao X; Bai Y; Han P; Chen S; Yang A; Gao R
Cancer Imaging; 2022 Dec; 22(1):72. PubMed ID: 36536432
[TBL] [Abstract][Full Text] [Related]
71. Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations.
Chernock RD; Rivera B; Borrelli N; Hill DA; Fahiminiya S; Shah T; Chong AS; Aqil B; Mehrad M; Giordano TJ; Sheridan R; Rutter MM; Dehner LP; Foulkes WD; Nikiforov YE
Mod Pathol; 2020 Jul; 33(7):1264-1274. PubMed ID: 31937902
[TBL] [Abstract][Full Text] [Related]
72. Mutational profiling of Chinese patients with thyroid cancer.
Du Y; Zhang S; Zhang G; Hu J; Zhao L; Xiong Y; Shen L; Chen R; Ye K; Xu Y
Front Endocrinol (Lausanne); 2023; 14():1156999. PubMed ID: 37465126
[TBL] [Abstract][Full Text] [Related]
73. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
74. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
[TBL] [Abstract][Full Text] [Related]
75. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
76. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
Kiyota N; Tahara M; Robinson B; Schlumberger M; Sherman SI; Leboulleux S; Lee EK; Suzuki T; Ren M; Fushimi K; Wirth LJ
Cancer; 2022 Jun; 128(12):2281-2287. PubMed ID: 35380178
[TBL] [Abstract][Full Text] [Related]
77.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
78. Anxiety and depression status prior to radioactive iodine therapy among differentiated thyroid cancer patients during the COVID‑19 pandemic.
Qiao T; Gao D; Tong J; Shen Y; Ma J; Lv Z; Li D
Support Care Cancer; 2022 Dec; 30(12):10169-10177. PubMed ID: 36326909
[TBL] [Abstract][Full Text] [Related]
79. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
[TBL] [Abstract][Full Text] [Related]
80. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
